Press Release Archives

  Tevogen Bio Reports Series A-1 Preferred Stock Investment at $10 Conversion Price       March 28, 2024   WARREN, N.J., Tevogen Bio Holdings (‘Tevogen Bio’) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in virology, oncology, and neurology, has entered into a securities purchase agreement withContinue reading “Tevogen Bio Reports Series A-1 Preferred Stock Investment at $10 Conversion Price”

  Tevogen Bio Reports Its Investigational SARS-CoV-2 Specific T Cell Therapy, TVGN-489, Retains Activity Against the Dominant JN.1 Variant       March 20, 2024   WARREN, N.J., Tevogen Bio Holdings (‘Tevogen Bio’) (Nasdaq: TVGN), today announced TVGN 489, its investigational allogeneic SARS-CoV-2 specific Cytotoxic CD8+ T lymphocytes (CTLs) immunotherapy for treatment of COVID-19 inContinue reading “Tevogen Bio Reports Its Investigational SARS-CoV-2 Specific T Cell Therapy, TVGN-489, Retains Activity Against the Dominant JN.1 Variant”

  Tevogen Bio Holdings Congratulates its Board Member and Esteemed Global Safety Management Expert, Victor Sordillo, on His appointment as Managing Director of Risk Advisory Services at Verita       March 5, 2024   WARREN, N.J., Tevogen Bio Holdings (‘Tevogen Bio’) (Nasdaq: TVGN), congratulates Victor Sordillo PE, CSP, MBA, on his recent appointment as Managing Director ofContinue reading “Tevogen Bio Holdings Congratulates its Board Member and Esteemed Global Safety Management Expert, Victor Sordillo, on His appointment as Managing Director of Risk Advisory Services at Verita”

      Mittul Mehta, Head of Tevogen’s Artificial Intelligence Initiative Tevogen.ai, Emphasizes Importance of Proactive Talent Development for Biopharmaceutical Sector to Allow Rapid Adoption of AI   Mittul Mehta, head of Tevogen’s artificial intelligence initiative Tevogen.ai, presenting his seminar “Artificial Intelligence Opportunities in Healthcare” at the Yale School of Public Health   February 27,Continue reading “Mittul Mehta, Head of Tevogen’s Artificial Intelligence Initiative Tevogen.ai, Emphasizes Importance of Proactive Talent Development for Biopharmaceutical Sector to Allow Rapid Adoption of AI”

  Cell Therapy Company Tevogen Bio Holdings Inc. Prepares to Launch Crucial Genetic Predisposition Study in Preparation to Investigate the Potential of TVGN 489 to Address Critical Unmet Need for Long COVID Treatment     February 21, 2024   WARREN, N.J. Tevogen Bio Holdings Inc. (‘Tevogen Bio’) (Nasdaq: TVGN)   Tevogen’s ExacTcell platform was developedContinue reading “Cell Therapy Company Tevogen Bio Holdings Inc. Prepares to Launch Crucial Genetic Predisposition Study in Preparation to Investigate the Potential of TVGN 489 to Address Critical Unmet Need for Long COVID Treatment”

  Cell Therapy Company Tevogen Bio Holdings Inc. (Nasdaq: TVGN) Rings Opening Bell at Nasdaq Exchange on February 15th, 2024, Begins Public Trading on the Open Market   Team Tevogen celebrating listing with Nasdaq   February 17, 2024   WARREN, N.J. Tevogen Bio Holdings Inc. (‘Tevogen Bio’) (Nasdaq: TVGN) celebrated commencement of its public tradingContinue reading “Cell Therapy Company Tevogen Bio Holdings Inc. (Nasdaq: TVGN) Rings Opening Bell at Nasdaq Exchange on February 15th, 2024, Begins Public Trading on the Open Market”

  Tevogen Bio Announces $8 Million Equity Investment   February 15, 2024   WARREN, N.J. On February 14, 2024, Tevogen Bio Holdings Inc. (the “Company”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in virology, oncology, and neurology, entered into a securities purchase agreement with an investor pursuantContinue reading “Tevogen Bio Announces $8 Million Equity Investment”

  Tevogen Bio Is Looking Forward to Closing Its Transaction With Semper Paratus   January 31, 2024   WARREN, N.J. Tevogen Bio Inc. (“Tevogen Bio”) is looking forward to and continues to work toward the anticipated closing of its proposed business combination with Semper Paratus Acquisition Corporation.   “Tevogen Bio’s business combination with Semper ParatusContinue reading “Tevogen Bio Is Looking Forward to Closing Its Transaction With Semper Paratus”

  Tevogen Bio Appoints Globally Prominent Physicist Specializing in Space Biology, COVID-19, and AI Democratization, Afshin Beheshti, to Advisory Board   The appointment of Afshin Beheshti, PhD, contributes to the diversity of thought leadership within Tevogen Bio by way of his roles as Bioinformatician and Principal Investigator at Blue Marble Space Institute of Science, PresidentContinue reading “Tevogen Bio Appoints Globally Prominent Physicist Specializing in Space Biology, COVID-19, and AI Democratization, Afshin Beheshti, to Advisory Board”

      Semper Paratus Acquisition Corporation Announces Anticipated Listing of Tevogen Bio Holdings Inc. on Nasdaq   January 24, 2024   New York, NY, Jan. 24, 2024  — Semper Paratus Acquisition Corporation (“Semper Paratus”) (Nasdaq: LGST, LGSTW), a publicly-traded special purpose acquisition company, today announced that it has filed a supplement (“Prospectus Supplement”) toContinue reading “Semper Paratus Acquisition Corporation Announces Anticipated Listing of Tevogen Bio Holdings Inc. on Nasdaq”